[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"complex-regional-pain-syndromes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:complex-regional-pain-syndromes":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,74,104,130,156,182,200,220,242,273,294,315,338],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100296322","tms-for-complex-regional-pain-syndrome-100296322",false,"NCT03137472","TMS for Complex Regional Pain Syndrome","Transcranial Magnetic Stimulation (TMS) for Complex Regional Pain Syndrome (CRPS)","Inclusion Criteria:\n\n* Age 18-70\n* Diagnosis of CRPS (complex regional pain syndrome) for at least 3 months\n* Average pain level reported on Numerical Rating Scale meets entry criteria\n* Ability to perform the experimental task and procedures.\n\nExclusion Criteria:\n\n* MRI contraindication (metal implants or devices, claustrophobia)\n* TMS Contraindication (eg metal implant or devices near the site of stimulation)\n* History of epilepsy\n* History of a psychological or psychiatric disorder that would interfere with study procedures, at the discretion of the researcher.\n* Neurologic illness that would interfere with brain integrity\n* Current medical condition or medication use that would interfere with study procedures or data integrity, at the discretion of the researcher.\n* Currently pregnant or planning to become pregnant.\n* On going legal action or disability claim.","ALL","18 Years","70 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of the current study is to assess the efficacy of TMS in the treatment of Complex Regional Pain Syndrome (CRPS). It is hypothesized that participants who receive TMS (Group 1) relative to sham treatment (Group 2) once daily for two days will demonstrate a greater improvement in CRPS-related pain and other associated symptomology (i.e., cognitive, emotional and physical) compared to baseline. Participants will be followed until they reach their baseline for two consecutive weeks to assess safety and duration of symptom alleviation.",[27],"Complex Regional Pain Syndromes",[29],"TMS, CRPS, Sham","RECRUITING","2026-06-18",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":34},"2017-04-24",{"date":38,"type":21},"2028-06-29",{"name":40,"class":41},"Stanford University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":42},"100492269","dance-therapy-and-chronic-pain-100492269","NCT05689944","Dance-therapy and Chronic Pain","Effect of Dance-therapy on Chronic Adolescent Pain Patients - a Randomized Controlled Trial Study","ALGODANCE","Inclusion Criteria:\n\n* Patients aged 12 to 20 years, girls or boys, with chronic pain.\n* Diagnosis of chronic pain made in a Pain Management Center\n* Patients followed in a Pain Management Center (to ensure that patients entering the protocol have pain that is not relieved by conventional treatments)\n* Patients who have given written consent for adults or whose parents have given consent for minors\n* Patients who are affiliated with or benefit from a social security system.\n\nExclusion Criteria:\n\n* Patients with other neurological or psychological disorders\n* Patients with psychiatric illnesses\n* Patients with chronic infectious, metabolic, cancerous, autoimmune diseases.\n* Non-communicating patients including deaf and hard of hearing patients\n* Patients or parents who do not speak or read French\n* Pregnant women\n* Dance or yoga professionals (dance or yoga teachers or those studying to become teachers)","12 Years","20 Years",{"count":54,"type":21},160,[24],"Pain, when it becomes chronic, can be a threat to patients and it is very common to observe a fear of pain and a fear of movement (kinesiophobia). Avoidance of movement due to fear of pain can lead to a deterioration of body image. Non-medicinal therapies are essential to correct this fear and movement avoidance behavior, to decrease \"catastrophic\" judgments and thus anxiety. The use of art-therapy in the accompaniment of patients with pain has shown, in particular, decreases in the intensity of pain, the level of anxiety, an improvement in stress, mood and overall psychological state. However, according to the current literature, it appears that 1) this technique is rarely used in children or adolescents, for whom non-medicinal therapies are fundamental, and 2) in the case of chronic pain, the form of art used is very rarely related to the body (most often painting, drawing, music...).\n\nIn this project, investigators propose to set up and test the potential benefit of art-therapy sessions related to the body, namely dance-therapy, in adolescents and young adults suffering from chronic pain.",[58,27,59],"Chronic Pain","Tension-Type Headache",[61,62,63,64,65],"Dance-therapy","Chronic pain","Complex Regional Pain Syndrome","Tension Type Headache","Adolescents","2026-06-16",{"date":31,"type":34},{"date":69,"type":34},"2024-03-01",{"date":71,"type":21},"2030-10",{"name":73,"class":41},"Hospices Civils de Lyon",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":42},"100501841","supraspinal-processing-of-sensory-aspects-of-pain-100501841","NCT05814497","Supraspinal Processing of Sensory Aspects of Pain","SCP","Inclusion Criteria:\n\n* Patients will need a diagnosis of a chronic pain derived congruent with ICD-11 criteria related to headache (migraine, daily headache), abdominal (FAPD), localized MSK (single limb\u002Fjoint, low back or chest pain), diffuse MSK (widespread MSK pain), or CRPS\n* If on medications, they need to be on stable doses of prescribed pain and\u002For psychiatric medications for 4 weeks before the baseline study visit.\n* Male or female, age 10 -17 (inclusive)\n* English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Weight\u002Fsize incompatible with MRI scanner\n* Orthodontic braces, metallic or electronic implants, or other metal objects in the body which obscure or interfere with the MRI, or pose a risk from heating, movement, or malfunction in the MRI environment\n* Claustrophobia\n* Youth who are pregnant\n* Any comorbid rheumatic disease, diagnosis of epilepsy, other neurological diseases, or medical condition (e.g. diabetes, cancer, IBD)\n* Present psychiatric disease as defined by DSM IV (e.g. psychosis, bipolar disorder, major depression, generalized anxiety disorder), alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, ADHD, or mental retardation) that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study\n* Skin conditions or past skin damage on the arms or legs in or near sites of sensory testing\n* Outside the age range (9 years old or younger; 18 years or older) at the time of consent\n* History of \\> 1 month opioid treatment.",true,"10 Years","17 Years",{"count":85,"type":21},255,[24],"The goal of this basic science study is to learn about the brain mechanisms of chronic pain across different chronic pain syndromes in pediatric patients. The main questions it aims to answer are:\n\n* Are there shared and distinct brain systems engaged by different forms of pediatric chronic pain?\n* What are predictors of recovery from chronic pain?\n* What brain systems are associated with the spread of pain?\n\nFor this study participants will undergo:\n\n* Functional Magnetic Resonance Imaging (fMRI)\n* Quantitative Sensory Testing\n* Psychological Assessments",[89,27,90,91,92],"Migraine in Children","Musculoskeletal Pain","Functional Abdominal Pain Syndrome","Fibromyalgia",[94],"chronic pain","2026-06-04",{"date":97,"type":34},"2026-06-05",{"date":99,"type":34},"2023-05-01",{"date":101,"type":21},"2027-06-30",{"name":103,"class":41},"Children's Hospital Medical Center, Cincinnati",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":81,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":42},"100550927","prednisone-for-crps-in-distal-radius-fracture-100550927","NCT06453447","Prednisone for CRPS in Distal Radius Fracture","Prednisone for the Early Treatment of Complex Regional Pain Syndrome After Distal Radius Fracture - a Pilot Randomized Trial","Inclusion Criteria:\n\n1. Patient is aged 19 years or older;\n2. Patient has a unilateral, closed, distal radius fracture confirmed by radiographs;\n3. The fracture is acute, within 21 days of injury;\n4. Patient undergoes open reduction internal fixation with volar locking plate;\n5. Patient is identified as at risk of developing CRPS with 2 or more of the following:\n\n   1. Pain score on visual analogue scale (VAS) greater than or equal to 5\u002F10 within 1 week of injury and beyond;\n   2. Centre of Epidemiologic Studies Depression (CES-D) score on presentation is greater than or equal to 16;\n   3. Patient identifies as female;\n6. Patient is identified as developing signs of CRPS based on the Budapest CRPS Criteria;\n7. Patient provides informed consent.\n\nExclusion Criteria:\n\n1. Patient has previously fractured ipsilateral wrist;\n2. Patient has neurovascular injury associated with distal radius fracture;\n3. Patient has associated extremity or polytrauma injuries that would interfere with rehabilitation and outcome measurements, in the opinion of the investigator;\n4. Patient has allergy to prednisone or placebo ingredients;\n5. Patient has contraindication to prednisone or placebo ingredients;\n6. Patient already takes a glucocorticoid medication;\n7. Patient has active bacterial, viral, or fungal infection;\n8. Patient is diagnosed with diabetes;\n9. Patient is pregnant, planning on becoming pregnant, or breastfeeding;\n10. Patient is anticipated to have difficulty completing study follow up, in the opinion of the investigator.","19 Years",{"count":20,"type":21},[24],"Wrist fractures are the most prevalent adult fracture. Complex regional pain syndrome (CRPS) is a common complication that can occur, leading to permanent disability and is costly to the patient and healthcare system. In addition, amidst the opioid epidemic, the risk of increased opioid use in patients with CRPS prompts the need to find viable treatment strategies. This study aims to evaluate an anti-inflammatory medication, prednisone, in the early treatment of CRPS. Patients with wrist fractures who undergo surgical treatment will be randomized to receiving placebo vs prednisone for 2 weeks. Clinical assessments in the follow up period will be compared.",[27,116],"Distal Radius Fractures",[118,119,120],"wrist fracture","pain","orthopaedic surgery","2026-04-27",{"date":123,"type":34},"2026-05-01",{"date":125,"type":34},"2024-10-10",{"date":127,"type":21},"2027-07",{"name":129,"class":41},"University of British Columbia",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":42},"100548360","phase-2-ketamine-hcl-prolonged-release-oral-tablets-for-crps-100548360","NCT06419985","Ketamine HCl Prolonged Release Oral Tablets for CRPS","A Phase 2 Single-arm, Open Label Clinical Trial to Evaluate the Efficacy of Ketamine HCl Prolonged Release Tablets in Participants With Complex Regional Pain Syndrome","Inclusion Criteria:\n\n1. Male and female participants between 18 and 64 years of age, inclusive, at Screening Visit.\n2. Participants with a documented history of CRPS of at least 6 months at Visit 1.\n3. At least one sign in two of the categories of The Budapest Criteria for CRPS to support the diagnosis of CRPS.\n4. Stable individual regular standard treatment regimen for CRPS pain, i.e., no change in drug and non-drug treatments for at least 4 weeks prior to Screening Visit and anticipated to remain stable throughout the study.\n5. No surgery, denervation procedures or neural blockade within 1 month of Screening Visit.\n6. Participants on ketamine therapy at Screening Visit must agree to discontinue use for at least 14 days prior to the Baseline Observation Period.\n7. Agree to discontinue any prohibited medications within prior to 14 days of the Baseline Observation Period and for the duration of the study.\n8. Average daily CRPS pain intensity score in the affected limb of ≥5 and ≤9 on an 11-point (0-10) NRS averaged over 7 days prior to Baseline Visit (Visit 1). This will be based on completion of at least 5 daily pain diary entries during the week prior to Visit 1, with no more than one 24-hour pain intensity score of zero or more than one 24-hour pain intensity score of 10.\n9. Participants willing and able (e.g., mental and physical condition) to participate in all aspects of the trial, including use of medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements as evidenced by providing signed written informed consent at Screening Visit.\n10. For persons of reproductive potential: use of highly effective contraception (females: barrier (condom, diaphragm, sponge, cervical cap) and\u002For oral, implantable rod, or intrauterine device birth control; males: barrier (condom)) for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 weeks after the end of study intervention administration.\n\nExclusion Criteria:\n\n1. Known or suspected cardiovascular disease, arrythmias, and\u002For respiratory issues.\n2. Abnormal EKG results, abnormal blood pressure (SBP \\\u003C90 or ≥ 140; DBP \\\u003C50 or ≥ 90) and\u002For heart rates (\\\u003C50 or \\>110).\n3. Known or suspected psychotic illness or neurologic disease.\n4. Known or suspected elevated intraocular and\u002For intracranial pressure.\n5. Known or suspected renal or urologic conditions or symptoms (i.e., bladder pain syndrome, interstitial cystitis), and\u002For abnormal baseline urinalysis results.\n6. Known or suspected hyperthyroidism.\n7. Allergy, hypersensitivity, or intolerance to ketamine or any of the investigational product excipients.\n8. Participants receiving opioids ≥30 mg\u002Fday morphine milligram equivalents (MME), whether as part of their individual standard treatment regimen for CRPS pain or in context with any other indication, within the last two weeks prior to Visit 1.\n9. Positive urine screen for any of the following: cocaine, amphetamine, methamphetamine, PCP, opioids, THC (other than medication used for individual standard treatment of pain) at Visit 1.\n10. Known or suspected acute or chronic alcoholism, delirium tremens, or toxic psychosis.\n11. Meet DSM-5 criteria for current or past substance use disorder within the last 5 years for any psychoactive substances other than nicotine or caffeine.\n12. Known hepatic dysfunction or serious liver disease, including presence of aspartate aminotransferase (AST) levels ≥ 2 X upper limit of normal and\u002For alanine aminotransferase (ALT) levels ≥ 2 X upper limit of normal and\u002For total bilirubin ≥ 1.5 X upper limit of normal\n13. Abnormal urinalysis, urine culture or abnormal creatinine\n14. Evidence of moderate or severe renal impairment (CRCL \\\u003C60 ml\u002Fmin) or participants with renal failure who are on any form of dialysis.\n15. Current or previous history of seizures.\n16. A positive pregnancy test\u002Fconfirmed pregnancy test at the screening or baseline visit.\n17. If Ask Suicide-Screening Questionnaire (ASQ) is positive at Grade 2 (moderate), subject will be excluded.\n18. Any other condition of the patient that in the opinion of the investigator may compromise evaluation of the trial treatment or may jeopardize participant's safety, compliance or adherence to protocol requirements.\n19. Previous enrollment in this trial or participation in any other clinical trial within the past 30 days prior to enrollment.","64 Years",{"count":139,"type":21},65,[141],"PHASE2","The purpose of this study is to evaluate the efficacy of Ketamine HCl Prolonged Release (PR) tablets in participants with pain due to complex regional pain syndrome (CRPS).\n\nAdditionally, this trial will explore the feasibility of the trial design through dosing compliance, clinical instruments for safety and quality of life measurements, and pharmacokinetic profile.",[27],[145],"CRPS","NOT_YET_RECRUITING","2026-01-22",{"date":149,"type":34},"2026-01-26",{"date":151,"type":21},"2026-07",{"date":153,"type":21},"2028-07",{"name":155,"class":41},"University of Southern California",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":167,"phases":4,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":42},"100499025","infrared-images-for-spinal-cord-stimulation-in-complex-regional-pain-syndrome-patients-100499025","NCT05777889","Infrared Images for Spinal Cord Stimulation in Complex Regional Pain Syndrome Patients","The Effect of Spinal Cord Stimulation on Thermal Forward Looking InfraRed (FLIR) Imaging in Complex Regional Pain Syndrome (CRPS)","SCS-FLIR","Inclusion Criteria:\n\n* The patient is between 18 and 85 years old\n* Providing CRPS diagnostic criteria by using the Budapest Clinical Diagnostic Criteria.\n* CRPS affecting unilateral lower extremity\n* The patient has had pain and other symptoms for more than 3 months\n* Not responding to conventional medical treatments and multidisciplinary approach\n* High NRS detection in pain assessment despite appropriate treatment (NRS= and \\> 6\u002F10).\n* Pain causing a limitation in the patient's functional capacity despite appropriate treatment.\n\nExclusion Criteria:\n\n* Patients with suspected disc herniation, spinal stenosis, myelopathy, and suspected radiculopathy in detailed examinations and examinations (MRI, CT).\n* Systemic or local infection\n* Coagulation disorders\n* History of allergy to contrast material\n* Malignancy\n* Pregnancy\n* Uncontrollable medical and psychiatric condition\n* The patients diagnosed with dysautonomia, sympathetic dysfunction other than CRPS (such as Raynaud disease or Buerger disease), sweating disorders other than CRPS (such as acquired idiopathic generalized anhidrosis), and patients","85 Years",{"count":166,"type":21},12,"OBSERVATIONAL","The goal of this observational study is to compare thermal camera Forward Looking InfraRed (FLIR) images before and after spinal cord stimulation to evaluate the difference in sympathetic activity of the affected limb in patients with complex regional pain syndrome (CRPS). The main questions it aims to answer are:\n\nQuestion 1: Can Infrared (FLIR) imaging be used to monitor the sympatholytic activity caused by Spinal Cord Stimulation (SCS) in patients with CRPS?\n\nQuestion 2: Is there any correlation between the quantification of sympatholytic activity produced by Spinal Cord Stimulation (SCS) and measured by FLIR imaging with the outcome measures in patients with CRPS? Outcome measures include pain (NRS), CRPS Severity Score (CSS), and neuropathic pain score (painDETECT).\n\nParticipants will have an image of their feet taken perpendicularly with a 1-inch space from all four sides using a FLIR T420 or T62101 camera with 320\\*240 resolution.\n\nParticipants will also complete questionnaires about the average pain, CRPS severity, and neuropathic pain.",[27],[171,172],"spinal","infrared","2025-11-19",{"date":175,"type":34},"2025-11-26",{"date":177,"type":34},"2023-02-22",{"date":179,"type":21},"2027-02",{"name":181,"class":41},"Hospital for Special Surgery, New York",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":167,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":198,"locationsCount":42},"100332739","role-of-the-gut-microbiome-in-complex-regional-pain-syndrome-100332739","NCT03612193","Role of the Gut Microbiome in Complex Regional Pain Syndrome","Study A: Cross-sectional study\n\nInclusion criteria, cases:\n\n* Adults over the age of 18\n* Current (\\\u003C 1 year duration) or former (\\> 1 year) diagnosis of Complex Regional Pain Syndrome by the Budapest criteria\n* English as primary language\n* able to consent\n\nInclusion criteria, controls\n\n* Adults over age of 18\n* Cohabitant of person with current or former diagnosis of CRPS\n\nStudy B: Longitudinal Study\n\nInclusion criteria, cases:\n\n* Adults over the age of 18\n* Recent diagnosis (\\\u003C6 months) of Complex Regional Pain Syndrome by the Budapest criteria\n* English as primary language\n* able to consent\n\nInclusion criteria, controls\n\n* Adults over age of 18\n* Cohabitant of person with diagnosis of CRPS\n\nStudy A and B: Exclusion criteria, cases and controls:\n\n* Unwilling to participate in the study\n* Lives alone\n* Current use of probiotics and unwilling to stop for 1 week prior to stool sample\n* Pregnant or lactating\n* Vegan diet",{"count":189,"type":21},140,"The objective of this prospective, observational study is to determine the association between the composition of the gut microbiota and the severity and persistence of Complex Regional Pain Syndrome symptoms (Study A). The objective of Study B, a longitudinal study of microbiota biomarkers of patients with newly diagnosed CRPS is to determine if the researchers can predict which patients are more likely to recover compared to those who do not. A secondary objective of both studies is to examine cognitive flexibility in relation to outcomes (study A and B).",[27],"2025-11-03",{"date":194,"type":34},"2025-11-05",{"date":196,"type":34},"2018-12-19",{"date":127,"type":21},{"name":199,"class":41},"Washington University School of Medicine",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":42},"100548465","closed-loop-spinal-cord-stimulation-for-complex-regional-pain-syndrome-100548465","NCT06421350","Closed Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome","Efficacy of Closed-Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome","Inclusion Criteria:\n\n* 18 years or older\n* neuromodulation naive patients with unilateral CRPS type 1 or type 2 (defined by Budapest Criteria)\n* pre-procedure psychological clearance\n\nExclusion Criteria:\n\n* younger than 18 years\n* prior neuromodulation including spinal cord stimulation\n* prior dorsal root ganglion stimulation\n* prior peripheral nervous system stimulation\n* anatomical obstacles to dorsal column lead placement",{"count":208,"type":21},32,[24],"The primary purpose of this study is to determine the differences in response to treatment of complex regional pain syndrome with a closed-loop spinal cord stimulator if applied in the early phases (acute or subacute) versus the chronic phase.",[27],"2025-10-30",{"date":192,"type":34},{"date":215,"type":34},"2024-09-03",{"date":217,"type":21},"2026-06",{"name":219,"class":41},"Scripps Health",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":42},"100441934","impact-of-compression-garments-on-pain-in-patients-with-complex-regional-pain-syndrome-of-the-upper-limbs-100441934","NCT05034835","Impact of Compression Garments on Pain in Patients With Complex Regional Pain Syndrome of the Upper Limbs.","Impact of Compression Garments on Neuropathic-looking Pain in Patients With Complex Regional Pain Syndrome (CRPS) of the Upper Limbs.","VECODON","Inclusion Criteria:\n\n* Patients with CRPS of the upper limb with neuropathic pain\n\n  * Diagnosis of CRPS according to the Budapest criteria\n  * Diagnosis of neuropathic pain according to DN4\n* CRPS evolving for more than 3 months\n* No phlebitis or open sores on the upper limbs\n* Patient consent to participate in the study\n* No modification of his drug treatment for 1 month\n* Affiliation to a social security scheme or beneficiary of such a scheme\n\nExclusion Criteria:\n\n* Patient under guardianship, curatorship or safeguard of justice\n* Psychiatric pathology altering the ability to consent\n* Severe cognitive disorders that do not allow the patient to assess his pain\n* Skin pathology preventing the wearing of the compression garment\n* Patient who has previously worn a compression garment\n* History of vascular disorders of the upper limbs, lymph node dissection, or any other pathology that can lead to edema regardless of CRPS\n* Known allergy to one of the components of the compression garments of the Cerecare brand\n* Declared pregnancy, breastfeeding woman or woman of childbearing potential without contraception\n* Inability to put on the compression garment alone",{"count":229,"type":21},60,[24],"The aim is to study another alternative for the treatment of pain in people with CRPS. Indeed, the TRAB \u002F Medullary occupational therapy department of the CMRRF in Kerpape used compression garments to reduce edema when it was present.In the case of CRPS of the upper limbs, gloves or compression sleeves are used to decrease the edema which is sometimes associated, although they are not supported for this indication. In this context, our clinical experience leads us to believe that there would also be some efficacy in neuropathic pain, this improvement being regularly described by patients.This study is expected to show a notable reduction in neuropathic pain thanks to the wearing of a compression garment.",[27],"2025-10-01",{"date":235,"type":34},"2025-10-06",{"date":237,"type":34},"2021-10-12",{"date":239,"type":21},"2026-10",{"name":241,"class":41},"Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":249,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":253,"conditions":254,"keywords":263,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":42},"100373633","closed-loop-deep-brain-stimulation-for-refractory-chronic-pain-100373633","NCT04144972","Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain","Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain Using Summit RC+S","Inclusion Criteria:\n\n1. Age 22-80 years old\n2. Clinical diagnosis of a refractory chronic pain syndrome including\n\n   1. post-traumatic pain syndromes (e.g. root avulsions, nerve crush injuries, spinal cord injury)\n   2. postsurgical pain syndromes (e.g., postmastectomy syndrome, post-thoracotomy syndrome, phantom limb pain, post-surgical spinal pain)\n   3. postherpetic neuralgia\n   4. complex regional pain syndrome\n   5. atypical facial pain\n   6. central pain syndromes (e.g. post-stroke pain, multiple sclerosis pain, post-radiation pain)\n   7. post-radiation plexopathy\n3. Two or more years or more of medically refractory severe pain\n4. Average daily pain for the past 30 days reported as \\>6 on a 0-10 numeric rating scale (NRS)\n5. Pain that fluctuates over a range of at least 3 points on the NRS\n6. Patient has failed at least two pain medications from different classes as determined by a neurologist or pain management specialist with stable doses of medications for 30 days prior to baseline visit.\n7. Lack of a surgically correctible etiology for the pain as determined by 2 independent surgeons\n8. Ability to speak \u002F read English\n9. Capable of understanding and providing informed consent\n10. Absence of significant cognitive impairment - score of 25 or greater on the Montreal Cognitive Assessment (MoCA)\n11. Successful detection of pain biomarkers or positive symptomatic response to inpatient stimulation trial period if performed.\n\nExclusion Criteria:\n\n1. Major medical co-morbidities increasing the risk of surgery including uncontrolled hypertension, coagulopathy, severe diabetes, major organ system failure, active infection or history of implant related infections, immunocompromised state or malignancy with \\\u003C 5 years life expectancy\n2. Presence of cardiac pacemakers\u002Fdefibrillators, implanted medication pumps, intra-cardiac lines, any intracranial implants (e.g., aneurysm clip, shunt, cochlear implant, electrodes) or other implanted stimulators not compatible with RC+S system\n3. Pregnancy or breast feeding: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure.\n4. Active depression (BDI \\> 20), Suicide attempt \\\u003C\u002F= 12 months or imminent suicide risk, or other untreated or uncontrolled psychiatric illness that evaluating psychiatrist would recommend exclusion of patient after neuropsychiatric evaluation.\n5. History of substance abuse in past 3 years\n6. Inability to stop anticoagulation or platelet anti-aggregation therapy for surgery and recovery.\n7. Implantable hardware not compatible with MRI or with the study.\n8. MR abnormalities that suggest an alternative diagnosis or contraindicate surgery\n9. Previous cranial ablative surgery.\n10. Previous deep brain stimulation surgery using an RC+S incompatible system\n11. Major neurological disorder other than the one that led to the chronic pain including epilepsy or a neurodegenerative condition including inability to recharge the device.\n12. Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS)\n13. Allergies or known hypersensitivity to materials in the Summit RC+S system\n14. Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from DBS.","22 Years","80 Years",{"count":166,"type":21},[24],"Chronic pain affects 1 in 4 US adults, and many cases are resistant to almost any treatment. Deep brain stimulation (DBS) holds promise as a new option for patients suffering from treatment-resistant chronic pain, but traditional approaches target only brain regions involved in one aspect of the pain experience and provide continuous 24\u002F7 brain stimulation which may lose effect over time. By developing new technology that targets multiple, complimentary brain regions in an adaptive fashion, the investigators will test a new therapy for chronic pain that has potential for better, more enduring analgesia.",[255,256,257,258,27,259,260,261,262],"Spinal Cord Injuries","Nerve Injury","Pain, Postoperative","Post Herpetic Neuralgia","Post-Stroke Pain","Post Radiation Brain Injury","Post Radiation Plexopathy","Nerve Root Avulsion",[58],"2025-07-02",{"date":266,"type":34},"2025-07-08",{"date":268,"type":34},"2019-10-24",{"date":270,"type":21},"2030-10-24",{"name":272,"class":41},"University of California, San Francisco",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":250,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100552245","thoracic-sympathetic-ganglion-block-with-botulinum-toxin-type-a-100552245","NCT06470581","Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A","Clinical Effect of Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A in Patients With Upper Extremity Complex Regional Pain Syndrome: A Prospective Randomized, Double-blind, and Comparative Clinical Trial","Inclusion Criteria:\n\n1. aged 19-80 years\n2. Diagnosed with a complex regional pain syndrome (type 1 or 2) in unilateral upper extremity\n3. 11-point numerical-rating-scale (NRS) pain score of 4 or higher in upper extremity\n4. Temperature increase at diagnostic thoracic sympathetic ganglion block\n5. Patients taking medication stably (without change in dosage\u002Frecipe) for more than 4 weeks prior to administration\n\nExclusion Criteria:\n\n1. Refusal of the patient\n2. Vascular disease at upper extremity\n3. previous thoracic sympathetic neurolysis (thermocoagulation, chemical neurolysis)\n4. coagulopathy\n5. systemic infection or local infection at thoracic puncture site\n6. significant deformity at thoracic spine\n7. neoplasm\n8. known allergic reaction with amide type local anesthetics\n9. cognitive dysfunction (not understanding of numerical-rating-scale)\n10. known allergic reaction with botulinum toxin\n11. pregnant or feeding women\n12. If the patient has participated in another clinical trial within 30 days before screening, or if passed no longer than 5-fold half-life of the clinical trial drug of the participating clinical trial",{"count":281,"type":21},78,[24],"Thoracic sympathetic ganglion block is a percutaneous procedure that paralyzes the action of sympathetic nerves transiently by injecting a local anesthetic around the ganglion. It is performed to diagnose and treat sympathetically maintained pain in phantom limb pain or complex reginal pain syndrome patient. The temperature of the affected arm is often lower than that of the opposite side. As a result of the procedure, the patient may experience sympathetic pain relief, such as coldness, stinging, numbness of the upper extremity. If the procedure does not last long, repetitive block or chemical neurolysis or radiofrequency thermocoagulation for the sympathetic ganglion is performed.\n\nHowever, even though in rare cases, chemical neurolysis is known to cause permanent plexus injury radiofrequency thermocoagulation is known to be less successful than chemical neurolysis because it is difficult to identify and stimulate the exact location of the ganglion. Therefore, it is expected that there will be a benefit to the patients if there is a procedure with long-lasting and avoiding injury.\n\nRecently, it has been reported that botulinum toxin (BTX) has been successfully used for the treatment of pain disorders. BTX plays a role with blocking the secretion of acetylcholine from the cholinergic nerve endings. Therefore, the use of BTX is expected to prolong the effect of neural blockade because pre-ganglia sympathetic nerves are cholinergic. It is also known that the action of BTX is not permanent and BTX does not exhibit cytotoxicity or neurotoxicity. Therefore, Botulinum toxin type A (BTA) is recommended for the treatment of migraine, myofascial pain syndrome, and neuropathic pain accompanied by allodynia. This study would like show whether thoracic sympathetic ganglion block using BTA has a longer duration than conventional local anesthesia by using prospective randomized, double-blind, parallel group, and comparative clinical trials.",[27],"2024-06-24",{"date":287,"type":34},"2024-06-26",{"date":289,"type":21},"2024-07-01",{"date":291,"type":21},"2027-04-25",{"name":293,"class":41},"Seoul National University",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":167,"phases":4,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":4},"100552076","sympatholytic-effects-of-high-thoracic-erector-spinae-plane-block-changes-in-optic-nerve-sheath-diameter-100552076","NCT06468384","Sympatholytic Effects of High Thoracic Erector Spinae Plane Block: Changes in Optic Nerve Sheath Diameter","Sympatholytic Effects of High Thoracic Erector Spinae Plane Block: A Prospective Observational Study on Changes in Optic Nerve Sheath Diameter","Inclusion Criteria:\n\n* Adults with neck, shoulder, and arm pain\n* Those with complex regional pain syndrome\n\nThe study will include 15 adult patients who are planned to receive T2-ESP block treatment.\n\n* Age between 18-65 years\n* Both genders\n* ASA physical status I-II\n\nExclusion Criteria:\n\n* Those who refuse procedures and tests\n* Individuals with conditions that can increase intracranial pressure\n* Those with severe heart failure\n* Individuals with second or third-degree atrioventricular block\n* Those with a history of unstable angina\n* Individuals with COPD or chronic asthma\n* Those who have experienced a myocardial infarction (MI) within the last 6 weeks\n* Individuals with a heart rate below 50 beats per minute\n* Those with systolic blood pressure below 90 mmHg\n* Individuals with liver failure\n* Those with kidney failure\n* Individuals for whom a supraclavicular block is anatomically impossible\n* Those with neurological or psychological conditions that complicate test evaluation\n* Individuals allergic to any of the study medications\n* Pregnant individuals","65 Years",{"count":303,"type":21},15,"The thoracic erector spinae plane (ESP) block is suggested to potentially affect the stellate ganglion, a key component of the sympathetic nervous system, thereby influencing autonomic functions. Changes in optic nerve sheath diameter (ONSD) are used as indicators of intracranial pressure changes. This study aims to investigate the effects of the ESP block on ONSD, providing insights into its impact on the stellate ganglion and enhancing the understanding of the ESP block's safety and efficacy.",[27],"2024-06-15",{"date":308,"type":34},"2024-06-21",{"date":310,"type":21},"2024-06-20",{"date":312,"type":21},"2024-09-20",{"name":314,"class":41},"Pamukkale University",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":42},"100484531","feasibility-study-of-combined-peripheral-nerve-block-and-physiotherapy-for-crps-100484531","NCT05589259","Feasibility Study of Combined Peripheral Nerve Block and Physiotherapy for CRPS","A Novel Treatment Approach to Complex Regional Pain Syndrome (CRPS): A Feasibility Study of Combined Peripheral Nerve Block and Physiotherapy","Inclusion Criteria:\n\n* Aged 18 years or older\n* Meets the Budapest criteria for CRPS of the upper extremity\n* Able to consent to treatment.\n\nExclusion Criteria:\n\n* Allergy to local anesthetic\n* Allergy to chlorhexidine\n* Infection at site of injection\n* Previous treatment of current CRPS with a regional anesthetic technique within 6 months\n* Unable to tolerate regional anesthesia or physiotherapy\n* Another pain condition that affects the same limb\n* Patient refusal or inability to consent.","110 Years",{"count":229,"type":21},[24],"Chronic pain is a debilitating condition affecting 1 in 5 Canadians with a yearly economic cost of over $40 billion in healthcare spending and loss of productivity. Since the prevalence of chronic pain is increasing, especially as the population ages, effective low-cost treatment is key to reduce the impact of chronic pain on patient quality of life and on healthcare costs. Due to the complexity of chronic pain and differences between the multitudes of pain conditions, developing effective treatments is challenging. This is especially true for Complex Regional Pain Syndrome (CRPS).\n\nCRPS is characterized by severe pain out of proportion to tissue trauma, with local autonomic and inflammatory changes. The severity of pain from CRPS may result in an inability to work, depression, sleep disorders, or suicidal ideation.\n\nAlthough its prevalence is low in Canada, CRPS is considered one the most debilitating and least understood pain conditions. As most current treatment options have low evidence of effectiveness, there is no definitive treatment available and most often, patients are struggling to maintain an acceptable quality of life. Thus, there is a pressing need to identify new and improved treatments for adults with CRPS.\n\nAn early hypothesis of CRPS pathophysiology posited that sympathetic nervous system over-activity led to many of the signs and symptoms of CRPS. As such, sympathetic nerve blocks, including stellate ganglion and lumbar sympathetic blocks, have been repeatedly investigated as a potential treatment of CRPS. However, a recent meta-analysis suggests that these blocks provided no benefits for those suffering with CRPS. Newer evidence suggests that a peripheral microvascular dysfunction may underlie CRPS pathophysiology. However, no clinical trials have investigated the efficacy of a treatment targeting this peripheral pathway.\n\nThe goal of this project is to assess the efficacy of a single-shot axillary approach to the brachial plexus block plus physiotherapy as a novel treatment protocol for CRPS. Our primary hypothesis is that providing a brachial plexus block in conjunction with a physiotherapy program would be superior to physiotherapy alone in treating pain and function in CRPS. Since this is a novel treatment protocol for CRPS, the purpose of our proposed study is to determine the feasibility of conducting a fully powered clinical trial.",[27],[94,328],"pain management","2024-03-12",{"date":331,"type":34},"2024-03-15",{"date":333,"type":21},"2025-02-01",{"date":335,"type":21},"2026-09-01",{"name":337,"class":41},"Tracy Cupido",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":81,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":345,"targetDuration":4,"studyType":167,"phases":4,"briefSummary":347,"conditions":348,"keywords":349,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":42},"100350076","markers-of-trajectory-in-pediatric-crps-100350076","NCT03838107","Markers of Trajectory in Pediatric CRPS","Identifying Markers of Trajectory in Pediatric Complex Regional Pain Syndrome","Inclusion Criteria:\n\nAll Children:\n\n* Age between 10 and 17 years old\n* Fluent in English\n\nInpatients:\n\n* Diagnosis of CRPS\n* Former unsuccessful treatment for CRPS\n* Scheduled for or beginning the usual inpatient treatment for CRPS at the FIRST clinic at CCHMC.\n\nOutpatients:\n\n* Diagnosis of CRPS\n* Scheduled for or beginning the usual outpatient treatment for CRPS at the pain management clinic\n\nHealthy children:\n\n\\- No diagnosis of chronic pain.\n\nParents:\n\n* Fluent in English\n* Child participating in the study\n\nExclusion Criteria:\n\nAll child participants:\n\n* Weight\u002Fsize incompatible with MRI scanner\n* Identification of brain, neurologic, or severe psychiatric abnormalities beyond those normally associated with chronic pain.\n* Documented developmental delays or impairment\n* Any MRI contra-indication, including\n* Braces, stents, clips, pace-maker or other metal implants affecting the safety of the participants in the scanner and\u002For the quality of the images\n* pregnancy\n* claustrophobia",{"count":346,"type":21},126,"Complex Regional Pain Syndrome (CRPS) is a severe and complex chronic pain condition in children. Many psychosocial factors impact its development and recovery. CRPS has a strong central component, which is reflected by structural and functional changes in the brain. However, the interaction between these cerebral changes and trajectory of recovery has been seldom investigated to date. Furthermore, interactions between cerebral changes and psychosocial factors, which might affect trajectory of recovery, are unknown. The aim of this study is to identify the psychosocial factors and cerebral changes that predict the trajectory of recovery from CRPS.\n\nChildren between the ages of 10 and 17 years will be enrolled with one of their parents or legal guardians for this study. Three populations will be recruited: patients with CRPS undergoing treatment at the Functional Independence Restoration Program (FIRST), patients with CRPS undergoing treatment at the Pain Management Center and matching healthy controls. Participants will undergo three sessions: the first session will be scheduled immediately before or as soon as possible at the beginning of the patients' treatment; the second session will take place at the end of the patients' treatment; the last session will be scheduled six months post-treatment. The timing of the sessions of the healthy participants will follow a schedule similar to the FIRST patients. Each session will last approximately three hours and include acquisition of psychosocial, psychophysical, and brain imaging data in the child participants, as well as acquisition of psychosocial data in the parent participants.",[27],[350,351,352,353,354],"pediatric complex regional pain syndrome","fMRI","psychosocial","quantitative sensory testing","markers","2024-02-05",{"date":357,"type":34},"2024-02-07",{"date":359,"type":34},"2018-08-27",{"date":361,"type":21},"2026-08-31",{"name":103,"class":41}]